Effect of quinidine on the 10-hydroxylation of R-warfarin: Species differences and clearance projection

Journal of Pharmacology and Experimental Therapeutics

Volumn 311, Issue 1, 2004, Pages 307-314

  Chen, Qing ^a   Tan, Eugene ^a   Strauss, John R ^a   Zhang, Zhoupeng ^a   Fenyk Melody, Judith E ^a   Booth Genthe, Catherine ^a   Rushmore, Thomas H ^a   Stearns, Ralph A ^a   Evans, David C ^a   Baillie, Thomas A ^a   Tang, Wei ^a  

^a MERCK RESEARCH LABORATORIES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

10 HYDROXYWARFARIN; QUINIDINE; UNCLASSIFIED DRUG; WARFARIN;

ANIMAL TISSUE; ARTICLE; BINDING SITE; CONTROLLED STUDY; DRUG BINDING; DRUG CLEARANCE; DRUG HYDROXYLATION; DRUG METABOLISM; DRUG STRUCTURE; ENZYME ACTIVITY; IN VITRO STUDY; LIVER MICROSOME; MALE; NONHUMAN; PRIORITY JOURNAL; RAT; SPECIES DIFFERENCE;

ANIMALS; DRUG INTERACTIONS; HYDROXYLATION; METABOLIC CLEARANCE RATE; MICROSOMES, LIVER; MUSCARINIC ANTAGONISTS; PERFUSION; QUINIDINE; RABBITS; RATS; SPECIES SPECIFICITY; WARFARIN;

EID: 4644276701     PISSN: 00223565     EISSN: None     Source Type: Journal    
DOI: 10.1124/jpet.104.069955     Document Type: Article

References (33)

1. Buening MK, Chang RL, Huang M-T, Fortner JG, Wood AW, and Conney AH (1981) Activation and inhibition of benzo(a)pyrene and aflatoxin B1 metabolism in human liver microsomes by naturally occurring flavonoids. Cancer Res 41:67-72.
2. Chow F-S, Piekoszewski W, and Jusko WJ (1997) Effect of hematocrit and albumin concentration on hepatic clearance if tacrolimus (FK506) during rabbit liver perfusion. Drug Metab Dispos 25:610-616.
3. Egnell A-C, Houston B, and Boyer S (2003) In vivo CYP3A4 heteroactivation is a possible mechanism for the drug interaction between felbamate and carbamazepine. J Pharmacol Exp Ther 305:1251-1262.
4. Fasco MJ, Vatsis KP, Kaminsky LS, and Coon MJ (1978) Regioselective and stereoselective hydroxylation of R and S warfarin by different forms of purified cytochrome P-450 from rabbit liver. J Biol Chem 253:7813-7820.
5. Guengerich FP (1997a) Role of cytochrome P450 enzymes in drug-drug interactions. Adv Pharmacol 43:7-35.
6. Guengerich FP (1997b) Comparison of catalytic selectivity of cytochrome P450 sub-family enzymes from different species. Chem Biol Interact 106:161-182.
7. Hosea NA, Miller GP, and Guengerich FP (2000) Elucidation of distinct ligand binding sites for cytochrome P450 3A4. Biochemistry 39:5929-5939.
8. Houston JB and Kenworthy KE (2000) In vitro-in vivo scaling of CYP kinetic data not consistent with the classic Michaelis-Menten model. Drug Metab Dispos 28: 246-254.
9. Huang M-T, Chang RL, Fortner JG, and Conney AH (1981) Studies on the mechanism of activation of microsomal benzo[a]pyrene hydroxylation by flavonoids, J Biol Chem 256:6829-6835.
10. Hutzler JM and Tracy TS (2002) Atypical kinetic profiles in drug metabolism reactions. Drug Metab Dispos 30:355-362.
11. Kaminsky LS, Fasco MJ, and Guengerich FP (1980) Comparison of different forms of purified cytochrome P-450 from rat liver by immunological inhibition of regio- and stereoselective metabolism of warfarin. J Biol Chem 255:85-91.
12. Kaminsky LS and Zhang Z-Y (1997) Human P450 metabolism of warfarin. Pharmacol Ther 73:67-74.
13. Koley AP, Buters JTM, Robinson RC, Markowitz A, and Friedman FK (1997) Differential mechanism of cytochrome P450 inhibition and activation by α-naphthoflavone. J Biol Chem 272:3149-3152.
14. Korzekwa KR, Krishnamachary N, Shou M, Ogai A, Parise RA, Rettie AE, Gonzalez FJ, and Tracy TS (1998) Evaluation of atypical cytochrome P450 kinetics with two-substrate models: evidence that multiple substrates can simultaneously bind to cytochrome P450 active sites. Biochemistry 37:4137-4147.
15. Kozlik P, Ha HR, Stieger B, Bigler L, and Follath F (2001) Metabolism of amiodarone (part III): identification of rabbit cytochrome P450 isoforms involved in the hydroxylation of mono-N-desethylamiodarone. Xenobiotica 31:239-248.
16. Lin JH and Lu AYH (1998) Inhibition and induction of cytochrome P450 and the clinical implications. Clin Pharmacokinet 35:361-390.
17. Mei Q, Tang C, Assang C, Slaughter D, Rodrigues DA, Rushmore TH, and Shou M (1999) Role of a potent inhibitory monoclonal antibody to cytochrome P450 3A4 in assessment of human drug metabolism. J Pharmacol Exp Ther 291:749-759.
18. Mesdjian E, Seree E, Charvet B, Mirrione A, Bourgarel-Rey V, Desobry A, and Barra Y (1999) Metabolism of carbamazepine by CYP3A6: a model for in vitro drug interactions studies. Life Sci 64:827-835.
19. Namkung MJ, Yang HL, Hulla JE, and Juchau MR (1988) On the substrate specificity of cytochrome P450IIIA1. Mol Pharmacol 34:628-637.
20. Ngui JS, Chen Q, Shou M, Wang R, Stearns RA, Baillie TA, and Tang W (2001) In vitro stimulation of warfarin metabolism by quinidine: increases in the formation of 4′- and 10-hydroxywarfarin. Drug Metab Dispos 29:877-886.
21. Obach RS (1997) Nonspecific binding to microsomes: impact on scale-up of in vitro intrinsic clearance to hepatic clearance as assessed through examination of warfarin, imipramine and propranolol. Drug Metab Dispos 25:1359-1369.
22. Obach RS (1999) Prediction of human clearance of twenty-nine drugs from hepatic microsomal intrinsic clearance data: an examination of in vitro half-life approach and nonspecific binding to microsomes. Drug Metab Dispos 27:1350-1359.
23. Omura T and Sato R (1964) The carbon monoxide-binding pigment of liver microsomes. I. Evidence for its hemoprotein nature. J Biol Chem 239:2370-2378.
24. Raucy JL and Lasker JM (1991) Isolation of P450 enzymes from human liver. Methods Enzymol 206:557-587.
25. Shou M, Dai R, Cui D, Korzekwa KR, Baillie TA, and Rushmore TH (2001) A kinetic model for the metabolic interaction of two substrates at the active site of cytochrome P450 3A4. J Biol Chem 276:2256-2262.
26. Tanaka E, Ishikawa A, and Horie T (1999) In vivo and in vitro trimethadione oxidation activity of the liver from various animal species including mouse, hamster, rat, rabbit, dog, monkey and human. Human Exp Toxicol 18:12-16.
27. Tang W and Stearns RA (2001) Heterotropic cooperativity of cytochrome P450 3A4 and potential drug-drug interactions. Curr Drug Metab 2:185-198.
28. Tang W, Stearns RA, Kwei GY, Iliff SA, Miller RR, Egan MA, Yu NX, Dean DC, Kumar S, Shou M, et al. (1999) Interaction of diclofenac and quinidine in monkeys: stimulation of diclofenac metabolism. J Pharmacol Exp Ther 291:1068-1074.
29. Tracy TS (2003) Atypical enzyme kinetics: their effect on in vitro-in vivo pharmacokinetic predictions and drug interactions. Curr Drug Metab 4:341-346.
30. Vaz ADN, McGinnity DF, and Coon MJ (1998) Epoxidation of olefins by cytochrome P450: evidence from site-specific mutagenesis for hydroperoxo-iron as an electrophilic oxidant. Proc Natl Acad Sci USA 95:3555-3560.
31. Wrighton SA and Stevens JC (1992) The human hepatic cytochromes P450 involved in drug metabolism. Crit Rev Toxicol 22:1-21.
32. Xu X, Selick P, and Pang KS (1993) Nonlinear protein binding and enzyme heterogeneity: effects on hepatic drug removal. J Pharmacokinet Biopharm 21:43-74.
33. Zhang Z, Li Y, Shou M, Zhang Y, Ngui JS, Stearns RA, Evans DC, Baillie TA, and Tang W (2004) Influence of different recombinant systems on the cooperativity exhibited by cytochrome P450 3A4. Xenobiotica 34:473-486.